All about health

Guardant Health, Inc. , a leading precision oncology company, today announced the company will participate in the following investor conferences. BofA Securities 2024 Healthcare Conference in Las Vegas Fireside Chat on Wednesday, May 15 at 10:40...

Biote , a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024...

Repare Therapeutics Inc. ("Repare" or the "Company") , a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024. "This was a quarter of clinical progress as we await key,...

YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

Exelixis, Inc. today announced that members of the company's management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2024 Health Care Conference: Exelixis is scheduled to present at 2:20...

Danaher Corporation announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to holders of record on June 28, 2024. ABOUT DANAHER     Danaher is a...

Cardinal Health announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the...

Neurocrine Biosciences, Inc. will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas. Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief...

The American College of Physicians (ACP) announced a new, three-year strategic priority expanding its commitment to, and support of, physicians in their engagement with continuous learning and professional accountability. ACP has long recognized the...

Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am...

Janux Therapeutics, Inc. (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated...

AbCellera today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "We continue to execute on advancing our internal pipeline,...

Veracyte, Inc. today announced financial results for the first quarter ended March 31, 2024. "We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We executed upon our strategies to...

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the first quarter ended March 31, 2024. Recent...

Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") , a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value...

Cryoport, Inc. (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months...

Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in two upcoming investor...

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m....

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of 2024 Topline results continue to be expected in the first half of 2025 for...

Penumbra, Inc. , a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024....

Labcorp , a global leader of innovative and comprehensive laboratory services, and Invitae , a leading medical genetics company,  announced today that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to...

Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of...

Nevro Corp. , a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results. The...

The U.S. Agency for International Development (USAID) Bureau for Global Health has awarded global consulting and technology services provider ICF a five-year, $236 million recompete contract to continue to deliver their Demographic and Health...

Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with...

Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.791 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance:...

First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 millionExpanded Rigel's portfolio with acquisition of GAVRETO®, a U.S. marketed product for RET...

Santa J. Ono, president of the University of Michigan, has joined the United States-Japan Foundation Board of Trustees. Ono, an accomplished medical researcher and leader in higher education across North America, is a second-generation Japanese...

CVS Health today announced that Chief Financial Officer Tom Cowhey will participate in a fireside chat with investors at the Bank of America 2024 Healthcare Conference on May 14, 2024, at approximately 7:20 a.m. pacific time. An audio webcast of the...